News
Desentum to present at the 2026 EAACI annual congress in Istanbul this week
Two abstracts related to Desentum’s product development projects have been accepted for presentation at the annual congress of the European Academy of Allergy and Clinical Immunology (EAACI) taking place in Istanbul, Türkiye, on Jun 12–15, 2026....
Summons to the Annual General Meeting of Desentum Oy
The shareholders of Desentum Oy are summoned to the company’s Annual General Meeting to be held on June 26th, 2026, at 10.00 (EEST) in Technopolis, Innopoli 2, Tekniikantie 14, 02150 Espoo.
Desentum’s 18 M€ share issue from private investors and family offices breaks a record for unlisted growth companies in Finland
Desentum’s 18 M€ share issue organised by the Finnish growth equity company Springvest marks the largest public share issue ever conducted in Finland by an unlisted growth company. The company is advancing a novel allergen immunotherapy platform that has the potential to make AIT treatments faster, more effective, and safer.
New scientific discovery about the molecular mechanism of allergic reaction sheds light on the severity of peanut allergy
A single Ara h 2 allergen can bind simultaneously three copies of an IgE antibody commonly found in peanut allergic patients. This enables the formation of large allergen-IgE complexes on mast cell or basophil surfaces and contributes to the potency of Ara h 2 in triggering allergic reactions and highlights its role in anaphylaxis.
Enrolment completed in Phase 2 clinical study with DM-101PX, a novel immunotherapy for treating birch pollen allergy
Desentum, a clinical-stage biotechnology company developing novel allergen immunotherapies, today announced that its Phase 2 clinical study evaluating DM‑101PX for the treatment of birch pollen allergy has completed enrolment. 97 participants...
Dosing started in Phase 2 clinical study with DM-101PX, a novel immunotherapy for treating birch pollen allergy
First trial participants have received their first doses in a Phase 2 clinical study, BASIT, evaluating DM-101PX for treatment of birch pollen allergy.
Phase 2 trial for birch pollen allergy treatment DM-101PX approved by Health Canada
The Canadian regulatory authority Health Canada has approved Desentum’s clinical trial application for a Phase 2 clinical study with DM-101PX, an investigational immunotherapeutic treatment for birch pollen allergy. Approximately 100 birch pollen...
Desentum to present clinical results of investigational birch pollen allergy vaccine DM-101PX and scientific discoveries about peanut allergy at the world’s largest allergy congress
All three abstracts submitted by Desentum have been accepted for oral presentations at the annual congress of the European Academy of Allergy and Clinical Immunology (EAACI) taking place in Glasgow, UK, on Jun 13–16, 2025. Two of the presentations...
Desentum reports strong safety and immunological data from Phase 1 clinical study with investigational birch pollen allergy vaccine DM-101PX
The short-course treatment was found to be safe and well tolerated in birch pollen allergic patients and to induce a very strong and sustained allergen-specific IgG4 response. DM-101PX-induced immunoglobulins were found to efficiently block IgE-mediated basophil activation endorsing the product’s potential to induce a protective immune response.
Desentum in the media
Here you can find links to articles about Desentum in international media. To see articles in Finnish media, change the language to Finnish from the upper right corner.